2 popular GLP-1 drugs linked to rare, life-threatening brain disorder

Key Points:

• Two widely used GLP-1 weight loss drugs, semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), have been linked to Wernicke encephalopathy (WE), a rare but serious brain condition caused by vitamin B1 deficiency.
• GLP-1 drugs slow digestion and reduce appetite, which can lead to inadequate nutrition and vitamin B1 deficiency, impairing brain cell function and potentially causing permanent brain damage or death if untreated.
• Researchers analyzing nearly 196,000 cases found 15 instances of WE disproportionately associated with these GLP-1 medications, often accompanied by gastrointestinal symptoms like vomiting and malnutrition, though classic WE symptoms are often absent, making diagnosis difficult.
• WE is treatable with early vitamin B1 supplementation, but without treatment, it can be fatal in up to 20% of cases and cause permanent brain damage in many survivors; clinicians are urged to monitor patients on GLP-1 drugs for signs of this condition.
• Besides GLP-1 drug users, individuals with chronic alcoholism, bariatric surgery patients, those with severe vomiting conditions like cannabinoid hyperemesis syndrome, and people with anorexia are also at increased risk for WE due to vitamin B1 deficiency.